Virally encoded interleukin-6 (vIL-6) coordinates with human IL-6 to modulate cytokine expression during KSHV infection
Kaposi Sarcoma-Associated Herpesvirus (KSHV) is characterized by its ability to establish lifelong infections that can lead to disease in immunocompromised individuals. Understanding the complex interactions between KSHV, the host cellular machinery, and the immune response is essential for unraveling the mechanisms underlying viral persistence and pathogenesis. KSHV extensively remodels the host gene expression landscape by inducing widespread RNA decay via the viral endoribonuclease SOX. While the vast majority of cellular mRNAs are degraded by SOX, select transcripts including Interleukin 6 (IL-6) escape degradation. Interestingly, KSHV encodes a viral homolog of the IL-6 transcript, known as viral interleukin-6 (vIL-6). Given the importance of IL-6 for KSHV biology and its ability to escape SOX-mediated decay, we explored how vIL-6 expression is regulated upon KSHV infection. Our data demonstrate that unlike IL-6, vIL-6 3'UTR does not provide protection from SOX degradation, yet vIL-6 mRNA steady state levels remain high throughout KSHV lytic cycle, suggesting a distinct transcriptional regulation. To assess the contributions of vIL-6 and IL-6 in modulating host genes expression, inflammatory signaling and KSHV-driven pathogenesis, we used a vIL-6 null viral mutant combined with an IL-6 knock down to perform transcriptomic analyses. This analysis revealed that depletion of IL-6, vIL-6 or both results in distinct alterations of the host gene expression environment, with differential effects on chemokine signaling and related pathways as well as a synergetic effect when both IL-6 and vIL-6 are present. Furthermore, functional assays confirmed vIL-6 alone is sufficient to activate key signaling pathways and pro-inflammatory responses, including the JAK/STAT pathway. Collectively, our findings suggest a mechanistic synergy between vIL-6 and IL-6 that may enhance KSHV-mediated immune modulation and contribute to viral persistence and tumorigenesis. Overall design: RNA-seq profiling of iSLK.BAC16 vIL-6-STOP ( Delta vIL-6, null) and vIL-6-ReV (revertant, WT) cells, with or without IL-6 knockdown, during KSHV latency and lytic reactivation at 48 hours